|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CEP170 |
Gene summary for CEP170 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CEP170 | Gene ID | 9859 |
| Gene name | centrosomal protein 170 | |
| Gene Alias | FAM68A | |
| Cytomap | 1q43 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5SW79 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9859 | CEP170 | LZE2T | Human | Esophagus | ESCC | 8.29e-04 | 6.43e-01 | 0.082 |
| 9859 | CEP170 | LZE4T | Human | Esophagus | ESCC | 2.65e-12 | 2.56e-01 | 0.0811 |
| 9859 | CEP170 | LZE7T | Human | Esophagus | ESCC | 1.69e-12 | 9.27e-01 | 0.0667 |
| 9859 | CEP170 | LZE8T | Human | Esophagus | ESCC | 3.94e-03 | 1.04e-01 | 0.067 |
| 9859 | CEP170 | LZE21D1 | Human | Esophagus | HGIN | 3.33e-03 | 2.11e-01 | 0.0632 |
| 9859 | CEP170 | LZE22T | Human | Esophagus | ESCC | 1.01e-05 | 4.14e-01 | 0.068 |
| 9859 | CEP170 | LZE24T | Human | Esophagus | ESCC | 7.19e-15 | 2.65e-01 | 0.0596 |
| 9859 | CEP170 | P2T-E | Human | Esophagus | ESCC | 1.06e-28 | 4.82e-01 | 0.1177 |
| 9859 | CEP170 | P4T-E | Human | Esophagus | ESCC | 1.39e-13 | 2.82e-01 | 0.1323 |
| 9859 | CEP170 | P5T-E | Human | Esophagus | ESCC | 3.97e-17 | 3.65e-01 | 0.1327 |
| 9859 | CEP170 | P8T-E | Human | Esophagus | ESCC | 1.18e-06 | 1.46e-01 | 0.0889 |
| 9859 | CEP170 | P9T-E | Human | Esophagus | ESCC | 9.19e-14 | 2.32e-01 | 0.1131 |
| 9859 | CEP170 | P10T-E | Human | Esophagus | ESCC | 2.65e-19 | 3.44e-01 | 0.116 |
| 9859 | CEP170 | P11T-E | Human | Esophagus | ESCC | 3.84e-10 | 4.86e-01 | 0.1426 |
| 9859 | CEP170 | P12T-E | Human | Esophagus | ESCC | 3.08e-25 | 5.10e-01 | 0.1122 |
| 9859 | CEP170 | P15T-E | Human | Esophagus | ESCC | 1.57e-16 | 3.87e-01 | 0.1149 |
| 9859 | CEP170 | P16T-E | Human | Esophagus | ESCC | 6.79e-34 | 6.78e-01 | 0.1153 |
| 9859 | CEP170 | P17T-E | Human | Esophagus | ESCC | 5.05e-04 | 2.92e-01 | 0.1278 |
| 9859 | CEP170 | P19T-E | Human | Esophagus | ESCC | 6.94e-09 | 6.69e-01 | 0.1662 |
| 9859 | CEP170 | P20T-E | Human | Esophagus | ESCC | 2.08e-11 | 3.00e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CEP170 | SNV | Missense_Mutation | novel | c.2514N>A | p.Ser838Arg | p.S838R | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| CEP170 | SNV | Missense_Mutation | c.1249N>A | p.Glu417Lys | p.E417K | Q5SW79 | protein_coding | deleterious(0.03) | benign(0.034) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CEP170 | SNV | Missense_Mutation | novel | c.1733N>G | p.Ser578Cys | p.S578C | Q5SW79 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CEP170 | SNV | Missense_Mutation | c.1186C>T | p.Leu396Phe | p.L396F | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CEP170 | SNV | Missense_Mutation | novel | c.3454N>G | p.Gln1152Glu | p.Q1152E | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| CEP170 | SNV | Missense_Mutation | c.986C>G | p.Pro329Arg | p.P329R | Q5SW79 | protein_coding | deleterious(0.01) | benign(0.347) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CEP170 | SNV | Missense_Mutation | novel | c.3943G>A | p.Glu1315Lys | p.E1315K | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CEP170 | SNV | Missense_Mutation | c.3439N>G | p.Ile1147Val | p.I1147V | Q5SW79 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CEP170 | SNV | Missense_Mutation | novel | c.1672N>A | p.Glu558Lys | p.E558K | Q5SW79 | protein_coding | tolerated(0.23) | benign(0.035) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| CEP170 | SNV | Missense_Mutation | novel | c.4630N>T | p.Leu1544Phe | p.L1544F | Q5SW79 | protein_coding | deleterious_low_confidence(0.05) | benign(0.122) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |